Targeting the proinflammatory cytokine tumor necrosis factor-α to alleviate cardiopulmonary bypass-induced lung injury (Review)

Molecular Medicine Reports

Volumn 11, Issue 4, 2015, Pages 2373-2378

  Gao, Mingxin ^a,b   Xie, Baodong ^c   Gu, Chengxiong ^a   Li, Haitao ^a   Zhang, Fan ^a   Yu, Yang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF HEART   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiopulmonary bypass; Lung injury; Tumor necrosis factor

Indexed keywords

NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

APOPTOSIS; CARDIOPULMONARY BYPASS; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG INJURY; LUNG PARENCHYMA; MONOCYTE; NONHUMAN; REVIEW; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; HUMANS; LUNG INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921342253     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3050     Document Type: Review

References (42)

1. Stamou SC, Pfister AJ, Dangas G, et al: Beating heart versus conventional single-vessel reoperative coronary artery bypass. Ann Thorac Surg 69: 1383-1387, 2000.
2. Asimakopoulos G, Smith PL, Ratnatunga CP and Taylor KM: Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 68: 1107-1115, 1999.
3. Hammermeister KE, Burchfiel C, Johnson R and Grover FL: Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation 82: 380-389, 1990.
4. Ng CS, Wan S, Yim AP and Arifi AA: Pulmonary dysfunction after cardiac surgery. Chest 121: 1269-1277, 2002.
5. Taggart DP, el-Fiky M, Carter R, Bowman A and Wheatley DJ: Respiratory dysfunction after uncomplicated cardiopulmonary bypass. Ann Thorac Surg 56: 1123-1128, 1993.
6. Wan S, LeClerc JL and Vincent JL: Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112: 676-692, 1997.
7. Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, Gummert J, Autschbach R and Mohr FW: Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, 'off-pump' technique, and conventional cardiopulmonary bypass. Circulation 102 (Suppl): III95-III100, 2000.
8. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA and Angelini GD: Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 69: 1198-1204, 2000.
9. Matata BM, Sosnowski AW and Galiñanes M: Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg 69: 785-791, 2000.
10. Zhang Z, Wu Y, Zhao Y, Xiao X, Liu J and Zhou X: Dynamic changes in HMGB1 levels correlate with inflammatory responses during cardiopulmonary bypass. Exp Ther Med 5: 1523-1527, 2013.
11. Qi D, Gao MX and Yu Y: Intratracheal antitumor necrosis factor-α antibody attenuates lung tissue damage following cardiopulmonary bypass. Artif Organs 37: 142-149, 2013.
12. Yu Y, Gao M, Li H, Zhang F and Gu C: Pulmonary artery perfusion with anti-tumor necrosis factor alpha antibody reduces cardiopulmonary bypass-induced inflammatory lung injury in a rabbit model. PLoS One 8: e83236, 2013.
13. Wan S, LeClerc JL and Vincent JL: Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 63: 269-276, 1997.
14. Welters ID, Feurer MK, Preiss V, Müller M, Scholz S, Kwapisz M, Mogk M and Neuhäuser C: Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth 106: 172-179, 2011.
15. Martínez-Comendador JM, Alvarez JR, Mosquera I, Sierra J, Adrio B, Carro JG, Fernández A and Bengochea J: Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery. Eur J Cardiothorac Surg 36: 998-1005, 2009.
16. Boehm J, Hauner K, Grammer J, Dietrich W, Wagenpfeil S, Braun S, Lange R and Bauernschmitt R: Tumor necrosis factor-α-863 C/A promoter polymorphism affects the inflammatory response after cardiac surgery. Eur J Cardiothorac Surg 40: e50-e54, 2011.
17. Yoon SZ, Jang IJ, Choi YJ, Kang MH, Lim HJ, Lim YJ, Lee HW, Chang SH and Yoon SM: Association between tumor necrosis factor alpha 308G/A polymorphism and increased proinflammatory cytokine release after cardiac surgery with cardiopulmonary bypass in the Korean population. J Cardiothorac Vasc Anesth 23: 646-650, 2009.
18. Galiñanes M, James M, Codd V, Baxi A and Hadjinikolaou L: TNF-alpha gene promoter polymorphism at nucleotide-308 and the inflammatory response and oxidative stress induced by cardiac surgery: role of heart failure and medical treatment. Eur J Cardiothorac Surg 34: 332-337, 2008.
19. Yewei X, Liya D, Jinghao Z, Rufang Z and Li S: Study of the mechanism of pulmonary protection strategy on pulmonary injury with deep hypothermia low flow. Eur Rev Med Pharmacol Sci 17: 879-885, 2013.
20. Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H and Li D: Simvastatin attenuates cardiopulmonary bypass-induced myocardial in fammatory injury in rats by activating peroxisome proliferator-activated receptor γ. Eur J Pharmacol 649: 255-262, 2010.
21. Dauber IM, Parsons PE, Welsh CH, Giclas PC, Whitman GJ, Wheeler GS, Horwitz LD and Weil JV: Peripheral bypass-induced pulmonary and coronary vascular injury. Association with increased levels of tumor necrosis factor. Circulation 88: 726-735, 1993.
22. Worrall NK, Chang K, LeJeune WS, Misko T P, Sullivan PM, Ferguson TB Jr and Williamson JR: TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms. Am J Physiol 273: H2565-H2574, 1997.
23. Petrache I, Verin AD, Crow MT, Birukova A, Liu F and Garcia JG: Differential effect of MLC kinase in TNF-alpha-induced endothelial cell apoptosis and barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 280: L1168-L1178, 2001.
24. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, Choudhary G, Oezatalay D and Uhal BD: Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 185: 253-259, 2000.
25. Faymonville ME, Pincemail J, Duchateau J, Paulus JM, Adam A, Deby-Dupont G, Deby C, Albert A, Larbuisson R, Limet R, et al: Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 102: 309-317, 1991.
26. Tsai CS, Chen DL, Lin SJ, Tsai JC, Lin TC, Lin CY, Chen YH, Huang GS, Tsai HY, Lin FY and Li CY: TNF-alpha inhibits toll-like receptor 4 expression on monocytic cells via tristetraprolin during cardiopulmonary bypass. Shock 32: 40-48, 2009.
27. Lee JC and Young PR: Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 59: 152-157, 1996.
28. Dong X, Liu Y, Du M, Wang Q, Yu CT and Fan X: P38 mitogen-activated protein kinase inhibition attenuates pulmonary inflammatory response in a rat cardiopulmonary bypass model. Eur J Cardiothorac Surg 30: 77-84, 2006.
29. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F and Balkwill FR: Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5: 382-390, 2006.
30. Lisby S, Faurschou A and Gniadecki R: The autocrine TNFalpha signalling loop in keratinocytes requires atypical PKC species and NF-kappaB activation but is independent of cholesterol-enriched membrane microdomains. Biochem Pharmacol 73: 526-533, 2007.
31. Imai Y, Kawano T, Iwamoto S, Nakagawa S, Takata M and Miyasaka K: Intratracheal anti-tumor necrosis factor-alpha antibody attenuates ventilator-induced lung injury in rabbits. J Appl Physiol (1985) 87: 510-515, 1999.
32. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R and Mann DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92: 1487-1494, 1995.
33. Katsura K, Park M, Gatanaga M, Yu EC, Takishima K, Granger GA and Gatanaga T: Identification of proteolytic enzyme which cleaves human p75 TNF receptor in vitro. Biochem Biophys Res Commun 222: 298-302, 1996.
34. Lantz M, Malik S, Slevin ML and Olsson I: Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2: 402-406, 1990.
35. Kapadia S, Torre-Amione G, Yokoyama T and Mann DL: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 268: H517-H525, 1995.
36. Wooley PH, Dutcher J, Widmer MB and Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602-6607, 1993.
37. Cain BS, Meldrum DR, Harken AH and McIntyre RC Jr: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186: 337-350, 1998.
38. Yamada H, Kudoh I, Hirose Y, Toyoshima M, Abe H and Kurahashi K: Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass. Acta Anaesthesiol Scand 40: 311-317, 1996.
39. Schulze CJ, Han L, Ghorpade N, Etches WS, Stang L, Koshal A and Wang SH: Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: a prospective randomized trial. J Card Surg 24: 363-368, 2009.
40. Apostolakis EE, Koletsis EN, Baikoussis NG, Siminelakis SN and Papadopoulos GS: Strategies to prevent intraoperative lung injury during cardiopulmonary bypass. J Cardiothorac Surg 5: 1, 2010.
41. Wiesner G, Braun SL, Gruber M, Gertler R, Lange R, Tassani P and Martin K: Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial. J Antimicrob Chemother 67: 230-233, 2012.
42. Morgan C, Zappitelli M and Gill P: Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review. Crit Care 13: R165, 2009.